What is Apriori Bio?
Apriori Bio, headquartered in Boston, MA, is a biotechnology firm dedicated to developing resilient protections against rapidly evolving viruses. The company's core innovation lies in a unique technology platform designed to survey the entire spectrum of existing and potential viral variants. This enables the creation of advanced vaccines capable of outmaneuvering viral evolution, thereby mitigating the impact of infectious diseases and offering humanity variant-resilient protection.
How much funding has Apriori Bio raised?
Apriori Bio has raised a total of $1.1M across 1 funding round:
Other Financing Round
$1.1M
Other Financing Round (2024): $1.1M with participation from Cepi Centre Enseignement Publications Informatiques
Key Investors in Apriori Bio
Cepi Centre Enseignement Publications Informatiques
Cepi Centre Enseignement Publications Informatiques is a French entity operating within the publishing sector, indicating a potential interest in knowledge dissemination or research-related ventures.
What's next for Apriori Bio?
With this substantial enterprise-level funding, Apriori Bio is poised to accelerate its research and development initiatives. The strategic investment will likely fuel the expansion of its platform capabilities, clinical trials, and the scaling of its operations to combat the global threat of viral pandemics. The company's focus on variant-resilient vaccines positions it as a key player in future public health preparedness.
See full Apriori Bio company page
